Tumor size at the time of adoptive transfer determines whether tumor rejection occurs

European Journal of Immunology

Volumn 30, Issue 5, 2000, Pages 1297-1307

  Cordaro, Tanina A ^a   De Visser, Karin E ^a   Tirion, Felicia H ^a   Graus, Yvo M F ^a,c   Haanen, John B A G ^a   Kioussis, Dimitris ^b   Kruisbeek, Ada M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c NUMICO RESEARCH   (Netherlands)

Author keywords

Adoptive transfer; Anti tumor response; CD8 T cell; Immune surveillance

Indexed keywords

CD8 ANTIGEN; EPITOPE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS NUCLEOPROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNOGENICITY; INFLUENZA VIRUS; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL;

EID: 0034023722     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C     Document Type: Article

References (42)

1. Rosenberg, S. A., Spiess, P. and Lafreniere, R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986. 233: 1318-1321.
2. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P. and White, D. E., Use of tumor-infiltrating lymphocytes and interleukin-2 in the imunotherapy of patients with metastatic melanoma. New Engl. J. Med. 1988. 319: 1676-1680.
3. Melief, C. J. M. and Kast, W. M., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 1995. 146: 167-177.
4. Yee, C., Riddell, S. R. and Greenberg, P. D., Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 1997. 9: 702-708.
5. Pape, K. A., Kearney, E. R., Khoruts, A., Mondino, A., Merica, R., Chen, Z.-M., Ingulli, E., White, J., Johnson, J. G. and Jenkins, M. K., Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cells for the study of T-cell activation in vivo, Immunol. Rev. 1997. 156: 67-78.
6. Kearney, E. R., Pape, K. A., Loh, D. Y. and Jenkins, M. K., Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994. 1: 327-339.
7. Rocha, B. and von Boehmer, H., Peripheral selection of the T cell repertoire. Science 1991. 251: 1225-1228.
8. Zhang, L., The fate of adoptively transferred antigen-specific T cells in vivo. Eur. J. Immunol. 1996. 26: 2208-2214.
9. + memory T cells in virus-infected hosts. J. Exp. Med. 1996. 183: 1367-1375.
10. Tanchot, C., Lemonnier, F. A., Pérarnau, B., Freitas, A. A. and Rocha, B., Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 1997. 276: 2057-2062.
11. + T cells upon in vivo stimulation with allogeneic tumor. J. Immunol. 1997. 159: 650-663.
12. Prévost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M. and Pircher, H., Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 1998. 161: 2187-2194.
13. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A. and Schreiber, H., Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 1997. 186: 229-238.
14. Marzo, A. L., Lake, R. A., Lo, D., Sherman, L., McWilliam, A., Nelson, D., Robinson, B. W. S. and Scott, B., Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 1999. 162: 5838-5845.
15. -/- mice. J. Immunol. 1997. 159: 4665-4675.
16. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H. and Zinkernagel, R. M., Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 1999. 96: 2233-2238.
17. Mamalaki, C., Elliott, J., Norton, T., Yannoutsos, N., Townsend, A. R., Chandler, P., Simpson, E. and Kioussis, D., Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 1993. 3: 159-174.
18. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. and Levitsky, H., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998. 95: 1178-1183.
19. Antoniou, A., McCormick, D., Scott, D., Yeoman, H., Chandler, P., Mellor, A. and Dyson, J., T cell tolerance and activation to a transgene-encoded tumor antigen. Eur. J. Immunol. 1996. 26: 1094-1102.
20. Kurts, C., Miller, J. F. A. P., Subramaniam, R. M., Carbone, F. R. and Heath, W. R., Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose anti-gens and those released during cellular destruction. J. Exp. Med. 1998. 2: 409-414.
21. Heath, W. R. and Carbone, F. R., Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 1999. 11: 314-318.
22. Carbone F. R., Kurts, C., Bennett, S. R. M., Miller, J. F. A. P. and Heath, W. R., Cross-presentation: a general mechanism for CTL immunity and tolerance, Immunol. Today 1998. 19: 368-373.
23. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994. 264: 961-965.
24. Schreiber H., Tumor immunology. In: Paul, W. E. (Ed.) Fundamental Immunology. Raven Press, New York 1993, p. 1143.
25. Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Plückthun, A., Elliott, T., Hengartner, H. and Zinkernagel, R. M., Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 1998. 187: 1383-1393.
26. Moskophidis, D., Lechner, F., Pircher, H., and Zinkernagel, R. M., Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993. 362: 758-761.
27. Chen, L., Linsley, P. S. and Hellström, K. E., Costimulation of T cells for tumor immunity, Immunol. Today 1993. 14: 483-486.
28. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., Löpez-Botet, M., Duggan-Keen, M. and Stern, P. L., Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997. 18: 89-95.
29. Seliger, B., Maeurer, M. J. and Ferrone, S., TAP off - tumors on Immunol. Today 1997. 18: 292-299.
30. Ranges G. E., Figari, I. S., Espevik, T. and Palladino, M. A., Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 1987. 166: 991-998.
31. O'Connell, J., O'Sullivan, G. C., Collins, J. K. and Shanahan, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996. 184: 1075-1082.
32. Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H. and Galle, P. R., Lymphocyte apoptosis induced by CD95 (APO-1/ Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nature Med. 1996. 2: 1361-1366.
33. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornard, T., Fontana, A., Lienard, D., Cerottini, J.-C. and Tschopp, J., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996. 274: 1363-1366.
34. Walker, P. R., Saas, P. and Dietrich, P.-Y., Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 1997. 158: 4521-4524.
35. Singh, S., Ross, S. R., Acena, M., Rowley, D. A. and Schreiber, H., Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 1992. 175: 139-146.
36. Mengersen, R., Schick, R. and Kölsch, E., Correlation of "sneaking through" of tumor cells with specific immunological impairment of the host. Eur. J. Immunol. 1975. 5: 532-537.
37. Deichman, G. I., Kluchareva, T. E., Kashkina, L. M. and Matveeva, V. A., Reproducibility and relation to specific and non-specific anti-tumor resistance of the tumor "sneaking through" phenomenon. Int. J. Cancer 1979. 23: 571-584.
38. Gatenby, P. A., Basten, A. and Creswick, P., "Sneaking through": a T-cell dependent phenomenon. Br. J. Cancer 1981. 44: 753-756.
39. Mombaerts, P., Lacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. and Papaioannou, V. E., RAG-1 -deficient mice have no mature B and T lymphocytes. Cell 1992. 68: 869-877.
40. Gorer, P. A., Studies in antibody response of mice to tumour inoculation. Br. J. Cancer 1950. 4: 372-379.
41. Heemskerk, M. H. M., Blom, B., Nolan, G., Stegmann, A. P. A., Bakker, A. Q., Weijer, K., Res, P. C. M. and Spits, H., Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 1997. 186: 1597-1602.
42. Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J. and Ahmed, R., Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 1998. 8: 177-187.